ZVRA
HEALTHCAREZevra Therapeutics Inc
$11.25+0.64 (+6.03%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ZVRA Today?
No stock-specific AI insight has been generated for ZVRA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.16$13.16
$11.25
Fundamentals
Market Cap$665M
P/E Ratio8.3
EPS$1.35
Dividend Yield—
Dividend / Share—
ROE0.9%
Profit Margin0.8%
Debt / Equity—
Trading
Volume2.1M
Avg Volume (10D)—
Shares Outstanding59.1M
ZVRA News
20 articles- Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?Yahoo Finance·May 7, 2026
- Zevra Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Zevra Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Zevra (ZVRA) Q1 2026 Earnings Call TranscriptMotley Fool·May 6, 2026
- Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass EstimatesYahoo Finance·May 6, 2026
- Zevra Reports First Quarter 2026 Financial Results and Corporate UpdateYahoo Finance·May 6, 2026
- Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- Zevra Therapeutics Announces Details for Q1 2026 Financial Results CallYahoo Finance·Apr 22, 2026
- Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage?Yahoo Finance·Mar 24, 2026
- Zevra Ties NPC Testing Push To Valuation Gap And New CFOYahoo Finance·Mar 23, 2026
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 20, 2026
- GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPCYahoo Finance·Mar 20, 2026
- Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 MillionYahoo Finance·Mar 16, 2026
- Zevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by ...Yahoo Finance·Mar 12, 2026
- Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price PerformanceYahoo Finance·Mar 11, 2026
- WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type CYahoo Finance·Mar 11, 2026
- Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?Yahoo Finance·Mar 11, 2026
- Why Zevra Therapeutics Stock Zoomed 21% Higher TodayMotley Fool·Mar 10, 2026
- GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type CYahoo Finance·Mar 10, 2026
- Zevra Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 9, 2026
All 20 articles loaded
Price Data
Open$10.19
Previous Close$10.61
Day High$10.34
Day Low$10.04
52 Week High$13.16
52 Week Low$7.16
52-Week Range
$7.16$13.16
$11.25
Fundamentals
Market Cap$665M
P/E Ratio8.3
EPS$1.35
Dividend Yield—
Dividend / Share—
ROE0.9%
Profit Margin0.8%
Debt / Equity—
Trading
Volume2.1M
Avg Volume (10D)—
Shares Outstanding59.1M
About Zevra Therapeutics Inc
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—